Journal Watch · Clinical Cancer Research · 2026
Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.
Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.
TL;DR
Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.
Key findings
- No significant differences in RFS or OS were observed by GM-CSF status.
- Participants vaccinated at two sites compared with one had significantly improved RFS [hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.38-0.93; P = 0.02] and a trend to improved OS (HR, 0.64; 95% CI, 0.39-1.06; P = 0.08).
- On landmark multivariable analysis, two-site vaccination was the only significant predictor of RFS (HR, 0.55; 95% CI, 0.34-0.88; P = 0.01) after adjusting for CD8+ T-cell response and other prognostic factors.<h4>Conclusions</h4>These results challenge the use of GM-CSF as a local vaccine adjuvant and support two-site vaccination.
- Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
C + D). For this analysis, overall survival (OS) and recurrence-free survival (RFS) were evaluated by these vaccine groups.<h4>Results</h4>All eligible participants (n = 121) were evaluated. The median follow-up was 5.6 years.
Full abstract (original)
Background: <h4>Purpose</h4>We report the long-term clinical outcomes of a multicenter, randomized phase II trial (NCT00089193) that tested immunogenicity of a vaccine composed of 12 class I MHC-restricted melanoma peptides (12MP), with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant and administered at one or two sites in patients with resected high-risk melanoma.<h4>Patients and methods</h4>Participants were randomized to one of four treatment arms: 12MP at one site (arm A), 12MP + GM-CSF at one site (arm B), 12MP at two sites (arm C), and 12MP + GM-CSF at two sites (arm D). The trial was powered to detect differences in immunogenicity by vaccine groups defined by GM-CSF status (arms B + D vs. A + C) and vaccine sites (arms A + B vs.
What they did: C + D). For this analysis, overall survival (OS) and recurrence-free survival (RFS) were evaluated by these vaccine groups.<h4>Results</h4>All eligible participants (n = 121) were evaluated. The median follow-up was 5.6 years.
Results & conclusions: No significant differences in RFS or OS were observed by GM-CSF status. Participants vaccinated at two sites compared with one had significantly improved RFS [hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.38-0.93; P = 0.02] and a trend to improved OS (HR, 0.64; 95% CI, 0.39-1.06; P = 0.08). On landmark multivariable analysis, two-site vaccination was the only significant predictor of RFS (HR, 0.55; 95% CI, 0.34-0.88; P = 0.01) after adjusting for CD8+ T-cell response and other prognostic factors.<h4>Conclusions</h4>These results challenge the use of GM-CSF as a local vaccine adjuvant and support two-site vaccination. Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.
Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-25-4606 · PubMed 41849224.
Why it matters for pharma & biotech
- Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: vaccines
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Clinical Cancer Research study find?
Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.
What type of study is this?
It is a randomised / controlled clinical trial, published in Clinical Cancer Research in 2026. C + D).
Where can I read the original paper?
The original is at the publisher via DOI 10.1158/1078-0432.ccr-25-4606. PubMed ID: 41849224. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/impact-of-gm-csf-and-two-site-vaccination-on-clinical-outcomes-after-mul-254606/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides